Phase 2 trial of first-line regorafenib with nivolumab and chemotherapy for advanced esophagogastric adenocarcinoma
Dr. Yelena Janjigian
Addition of nivolumab to chemotherapy improves survival in patients with advanced esophagogastric (esophageal, gastric, or gastro-esophageal junction) adenocarcinoma, but outcomes remain poor. A phase 2 trial at Memorial Sloan Kettering Cancer Center (New York, NY) evaluated the combination of regorafenib with nivolumab and FOLFOX chemotherapy for HER2-negative advanced esophagogastric adenocarcinoma. The combination was safe, with no treatment-related deaths, and showed promising activity.
